Symbol="CVAC"
AssetType="Common Stock"
Name="CureVac NV"
Description="CureVac NV, a clinical-stage biopharmaceutical company, is focused on developing various transformative drugs based on messenger ribonucleic acid (mRNA). The company is headquartered in Tbingen, Germany."
CIK="1809122"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="PAUL-EHRLICH-STRABE 15 TUBINGEN, BADEN-WURTTEMBERG, DE"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="1970170000"
EBITDA="-239502000"
PERatio="None"
PEGRatio="None"
BookValue="2.899"
DividendPerShare="0"
DividendYield="0"
EPS="-1.58"
RevenuePerShareTTM="0.184"
ProfitMargin="0"
OperatingMarginTTM="-6.68"
ReturnOnAssetsTTM="-0.172"
ReturnOnEquityTTM="-0.473"
RevenueTTM="37609000"
GrossProfitTTM="-91549000"
DilutedEPSTTM="-1.58"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="-0.624"
AnalystTargetPrice="14.88"
TrailingPE="-"
ForwardPE="9.17"
PriceToSalesRatioTTM="13.29"
PriceToBookRatio="2.071"
EVToRevenue="8.61"
EVToEBITDA="-8.89"
Beta="2.781"
num_52WeekHigh="12.79"
num_52WeekLow="5.63"
num_50DayMovingAverage="9.69"
num_200DayMovingAverage="8.63"
SharesOutstanding="223883000"
DividendDate="None"
ExDividendDate="None"
symbol="CVAC"
open="8.82"
high="8.93"
low="8.66"
price="8.80"
volume="157175.00"
latest_trading_day="2023-08-25"
previous_close="8.79"
change="0.01"
change_percent="0.1138%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="41"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="59"
Volume_recent_avg="577429"
Change_recent_avg="0.02"
Delta_recent_avg="0.57"
Variance_recent_avg="0.29"
Change_ratio_recent_avg="0.13"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="59"
Aroon_momentum_negative="41"
image_negative_thumbnail_id_1="148"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0028.jpeg"
image_negative_thumbnail_id_2="1089"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0122.jpeg"
image_neutral_thumbnail_id_1="594"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0005.jpeg"
image_neutral_thumbnail_id_2="526"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0073.jpeg"
image_positive_thumbnail_id_1="630"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0078.jpeg"
image_positive_thumbnail_id_2="703"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0005.jpeg"
image_professor_thumbnail_id_1="1192"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0026.jpeg"
image_professor_thumbnail_id_2="1179"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0013.jpeg"
